People are different and so is their cancer, patients should be treated individually.

Clinical programs

2cureX runs multiple clinical studies at several international clinical centers. As we conduct clinical trials, the body of information on treatment efficacy per patient is expanding and made available as a database to support testing.

Central to our study programs are the IndiTreat biobank and the IndiBase data repository. The IndiTreat biobank contains samples used as reference material when profiling patients based on drug sensitivity. The IndiBase data repository is an important resource for comparative sensitivity studies.

Microtumors not used with the IndiTreat® test are stored in the IndiTreat® biobank.

All data are stored in 2cureX’s database, IndiBase.

Want to know more?

Want to know more?

Contact us

Please contact 2cureX for more information

Phone: +45 22115399

Upcoming events

February 23, 2023

Year-End Report 2022 released

View previous reports

Key benefits of IndiTreat

  • Tumor resistance
    Predict tumor resistance and sensitivity to cancer drugs
  • Right cancer treatment
    Select the most appropriate treatment, in accordance with guidelines or off-label
  • Better patient outcome
    Improve patient quality of life through in vitro testing of drug efficacy on the individual patient
  • Help chemo-naïve CRC patients
    Identify the most effective treatment in chemo-naïve colorectal cancer patients
  • Help late-stage CRC patients
    Identify the most effective treatment in late-stage colorectal cancer patients
  • Functional precision medicine
    Complement the genomic characterisation of tumours with functional data on resistance and sensitivity to drugs